Insulet Corporation (PODD) had a lucrative year with share prices gaining more than 49% in the last five years. At the end of its fourth quarter in 2024, it announced financial results placing its share price target at $300 by BTIG and $324 by TD Cowen. The Q3 revenue soared 26% with the company gaining 10% in stock in a week. Insulet unveiled its new Omnipod 5 system in France with up to date innovation updates and an approval from FDA for Type 2 Diabetes. Despite the concern about user growth, the company showed optimistic signs, with the Omnipod 5 system integrated with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S. Insulet's solid profits showed results but were marked by weak fundamentals. Legal issues regarding patents kept the company in court; however, the year ended with a grand opening in Malaysia and a high at $248.55.
Insulet Corporation PODD News Analytics from Thu, 22 Feb 2024 08:00:00 GMT to Fri, 10 Jan 2025 11:00:00 GMT -
Rating 7
- Innovation 5
- Information 7
- Rumor -6
